Drug Profile
Research programme: non-absorbed polymeric therapeutics - Relypsa
Alternative Names: RLY 6002Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Relypsa
- Class Polymers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Kidney disorders; Metabolic disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 28 Apr 2018 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Apr 2018 No recent reports of development identified for research development in Kidney-disorders in USA